Halozyme Therapeutics Inc. Common Stock (HALO)
Stock · NASDAQ · Health Care
$121.82as of 10/16/2026
Price chart
Active signals
HALO Signal Track Record
How signals performed across all stocks →What HALO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | +2.2% | 54% | September 8, 2026 |
| Bollinger Band BreakoutActive now | 27 | +4.4% | 63% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 20 | -1.2% | 50% | June 3, 2026 |
| Bollinger Band Breakdown | 17 | -1.2% | 47% | December 3, 2025 |
| Any 20-session window (baseline) | +2.8% | 58% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HALO
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as wel…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 423
- Website
- www.halozyme.com/
Fundamentals
- 1-day range
- $117.38$122.33
- Market cap
- $10.17B
- P/E (trailing)
- 32.51
- P/E (forward)
- 11.38
- EPS (trailing)
- $3.35
- Dividend yield
- —
- Beta
- 0.94
- Avg. volume
- 2.23M
How Halozyme Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Halozyme Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- HALOHalozyme Therapeutics Inc. Common Stock$121.84▲ 0.27%Market cap $10.17BP/E 32.51$61.23$119.21
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
- RGENRepligen Corporation Common Stock$175.42▼ 4.75%Market cap $9.00BP/E 244.54$100.99$198.87
- KYMRKymera Therapeutics Inc. Common Stock$104.78▼ 3.11%Market cap $8.75BP/E —$55.26$130.05
- QGENQiagen N.V. Common Shares$46.13▼ 0.09%Market cap $8.60BP/E 22.92$32.53$57.82
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HALO Halozyme Therapeutics Inc. Common Stock | $10.17B | 32.51 | $121.84 | ▲ 0.27% | $61.23$119.21 |
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
| RGEN Repligen Corporation Common Stock | $9.00B | 244.54 | $175.42 | ▼ 4.75% | $100.99$198.87 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.75B | — | $104.78 | ▼ 3.11% | $55.26$130.05 |
| QGEN Qiagen N.V. Common Shares | $8.60B | 22.92 | $46.13 | ▼ 0.09% | $32.53$57.82 |
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130benzinga · 10/13/2026
- Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong ProfitabilityChartMill · 10/9/2026
- JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78Benzinga · 10/8/2026
- HALO Wins Court Order Blocking Merck's Keytruda SC in EuropeYahoo · 10/8/2026
- HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130Benzinga · 10/8/2026
- Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value?Yahoo · 10/8/2026
- Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?Yahoo · 10/7/2026
- Sector Update: Healthcare Stocks Rise Late AfternoonYahoo · 10/7/2026
- Sector Update: Healthcare Stocks Rise in Afternoon TradingYahoo · 10/7/2026
Insider Activity
Insider Actions →- Helen Torley · October 8, 2026 · Option Exercise20.0K @ $18.41
- Helen Torley · October 8, 2026 · Sale200 @ $110.51
- Helen Torley · October 8, 2026 · Sale11.9K @ $110
- Helen Torley · October 8, 2026 · Sale3.1K @ $108.91
- Helen Torley · October 8, 2026 · Sale4.8K @ $108.18
- Helen Torley · October 7, 2026 · Option Exercise20.0K @ $18.41
- Helen Torley · October 7, 2026 · Sale200 @ $113.69
- Helen Torley · October 7, 2026 · Sale900 @ $112.78
- Helen Torley · October 7, 2026 · Sale10.3K @ $111.84
- Helen Torley · October 7, 2026 · Sale8.6K @ $111.03
- Helen Torley · October 6, 2026 · Option Exercise20.0K @ $18.41
- Helen Torley · October 6, 2026 · Sale1.8K @ $110.81
- Helen Torley · October 6, 2026 · Sale9.9K @ $109.89
- Helen Torley · October 6, 2026 · Sale6.0K @ $109.33
- Helen Torley · October 6, 2026 · Sale2.3K @ $107.9
Institutional Ownership
March 31, 2026
- Total shares held
- 113.86M
- Total value held
- $7.04B
- Institutional holders
- 622
- Unknown13.27M
- Unknown5.27M
- Unknown4.94M
- Unknown4.01M
- Unknown2.91M
- Unknown2.68M
- Unknown2.56M
- Unknown2.53M
- Unknown2.51M
- Unknown2.32M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review
Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review. Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.